SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Decrease in Short Interest

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 6,080,000 shares, a decrease of 25.7% from the September 30th total of 8,180,000 shares. Based on an average daily volume of 593,700 shares, the short-interest ratio is presently 10.2 days.

Hedge Funds Weigh In On SELLAS Life Sciences Group

A hedge fund recently bought a new stake in SELLAS Life Sciences Group stock. Renaissance Technologies LLC purchased a new position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,446 shares of the company’s stock, valued at approximately $39,000. Renaissance Technologies LLC owned approximately 0.06% of SELLAS Life Sciences Group at the end of the most recent quarter. 17.38% of the stock is owned by institutional investors.

SELLAS Life Sciences Group Price Performance

Shares of SLS traded up $0.13 during mid-day trading on Friday, reaching $1.23. 1,015,327 shares of the company’s stock traded hands, compared to its average volume of 1,096,079. The stock’s 50-day moving average is $1.25 and its two-hundred day moving average is $1.28. SELLAS Life Sciences Group has a 12 month low of $0.50 and a 12 month high of $1.72. The stock has a market cap of $71.04 million, a P/E ratio of -1.12 and a beta of 2.39.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. Research analysts predict that SELLAS Life Sciences Group will post -0.55 earnings per share for the current year.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.